Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
DVAX | US
-0.33
-2.91%
Healthcare
Biotechnology
30/06/2024
04/10/2024
11.02
11.25
11.36
10.94
Dynavax Technologies Corporation a commercial stage biopharmaceutical company focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018 the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals Inc.; Clover Biopharmaceuticals (Hong Kong) Co. Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville California.
View LessValue Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
26.3%1 month
26.3%3 months
35.2%6 months
32.2%84.62
54.95
2.24
0.40
0.25
28.93
3.83
-
-7.87M
1.44B
1.44B
-
10.03
207.20
22.50
2.82
9.82
16.83
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.93
Range1M
1.02
Range3M
1.96
Rel. volume
0.77
Price X volume
15.54M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
BioCryst Pharmaceuticals Inc | BCRX | Biotechnology | 7.58 | 1.57B | 2.71% | n/a | -178.85% |
Belite Bio Inc | BLTE | Biotechnology | 50.99 | 1.56B | 4.68% | n/a | 0.00% |
Immunocore Holdings plc | IMCR | Biotechnology | 31.11 | 1.56B | 0.06% | n/a | 131.69% |
Ocular Therapeutix Inc | OCUL | Biotechnology | 9.84 | 1.53B | 5.69% | n/a | 19.83% |
Arcus Biosciences Inc | RCUS | Biotechnology | 16.65 | 1.52B | 8.19% | n/a | 1.73% |
Rocket Pharmaceuticals Inc | RCKT | Biotechnology | 16.41 | 1.49B | -3.24% | n/a | 6.71% |
IRON | IRON | Biotechnology | 49.93 | 1.48B | -2.48% | n/a | 0.38% |
Cassava Sciences Inc | SAVA | Biotechnology | 27.08 | 1.45B | 0.52% | n/a | 0.00% |
NRIX | NRIX | Biotechnology | 22.2 | 1.43B | 1.05% | n/a | 7.77% |
Longboard Pharmaceuticals Inc. Common Stock | LBPH | Biotechnology | 36.22 | 1.41B | -0.55% | n/a | 1.31% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 28.93 | 0.76 | Expensive |
Ent. to Revenue | 3.83 | 3,674.48 | Cheaper |
PE Ratio | 84.62 | 38.01 | Expensive |
Price to Book | 2.24 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 35.23 | 74.67 | Lower Risk |
Debt to Equity | 0.40 | -1.82 | Expensive |
Debt to Assets | 0.25 | 0.26 | Par |
Market Cap | 1.44B | 3.73B | Emerging |